US · LIVN
LivaNova PLC
- Sector
- Healthcare · Medical - Devices
- Headquarters
- London W2 6LG
- Website
- livanova.com
Price · as of 2025-12-31
$61.00
Market cap 3.86B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $76.59 | +25.56% |
| Intrinsic Value(DCF) | $36.57 | -40.05% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $14.58 | $35.21 | |||
| 2012 | $13.08 | $28.89 | |||
| 2013 | $16.71 | $40.00 | |||
| 2014 | |||||
| 2015 | $20.78 | $48.43 | |||
| 2016 | $49.22 | $81.22 | $13,605.57 | $14.35 | $0.00 |
| 2017 | $87.55 | $62.55 | $48.98 | $18.79 | $4.04 |
| 2018 | $92.65 | $49.44 | $242.79 | $0.00 | $0.00 |
| 2019 | $72.58 | $50.96 | $0.00 | $0.00 | $0.00 |
| 2020 | $78.01 | $41.16 | $0.00 | $0.00 | $36.39 |
| 2021 | $71.52 | $79.11 | $3.50 | $0.00 | $0.00 |
| 2022 | $41.20 | $40.57 | $0.00 | $0.14 | $0.00 |
| 2023 | $53.73 | $49.89 | $0.00 | $10.81 | $6.63 |
| 2024 | $39.17 | $46.63 | $1.05 | $16.34 | $19.07 |
| 2025 | $70.27 | $76.59 | $14.48 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates LivaNova PLC's (LIVN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $76.59
- Current price
- $61.00
- AI upside
- +25.56%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$36.57
-40.05% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| LIVN | LivaNova PLC | $61.00 | 3.86B | +26% | -40% | — | — | -15.79 | 3.19 | 2.76 | -28.32 | — | 21.61 | 67.71% | 14.36% | -17.47% | -19.24% | 15.30% | -9.49% | 0.39 | 4.04 | 1.36 | 1.05 | 1.25 | -48362.00% | 1074.00% | 2742.00% | 4.52% | 0.31 | 13.29% | 0.00% | 0.00% | 10.83% | 18.39 | 21.17 | 2.64 | 2.55 |
| ATEC | Alphatec Holdings, Inc. | $13.62 | 2.02B | +183% | +162% | — | — | -14.10 | 56.10 | 2.65 | -62.48 | — | -15.24 | 69.60% | -10.75% | -18.76% | -630.66% | -16.83% | -18.30% | 17.21 | -3.88 | 2.06 | 1.18 | -11.57 | -1504.00% | 2495.00% | -10201.00% | 0.14% | 0.21 | 0.57% | 0.00% | 0.00% | 0.59% | -30.20 | 893.55 | 3.25 | 0.06 |
| CDTX | Cidara Therapeutics, Inc. | $221.38 | 5.61B | -67% | -96% | — | +934% | -0.88 | 0.92 | 117.83 | 0.20 | -0.22 | 0.92 | -6557.49% | -13811.92% | -13319.76% | -218.99% | 567.59% | -120.52% | 0.02 | — | 4.25 | 3.86 | 1.06 | 40952.00% | -9800.00% | 67021.00% | -117.59% | -3.56 | 569.40% | 0.00% | 0.00% | 103.41% | 0.20 | 0.20 | -28.25 | -4.03 |
| HTFL | Heartflow, Inc. Common St… | $23.16 | 1.97B | — | — | — | — | — | — | — | — | — | — | 75.07% | -48.66% | -76.65% | 11.78% | 8.22% | -63.49% | -0.19 | -2.69 | 2.45 | 2.33 | -1.67 | -2320.00% | 4432.00% | -1112.00% | — | -2.05 | 9.85% | — | 0.00% | — | — | — | — | — |
| IDYA | IDEAYA Biosciences, Inc. | $32.20 | 2.83B | +1,323% | +773% | -84% | — | -25.71 | 2.86 | 13.37 | -14.94 | — | 2.86 | 97.90% | -72.84% | -51.99% | -10.92% | -39.17% | -10.18% | 0.03 | — | 11.34 | 10.87 | 0.55 | -6190.00% | 302443.00% | -7078.00% | -2.51% | -1.21 | -18.06% | 0.00% | 0.00% | 0.67% | -14.51 | -31.47 | 10.57 | 19.76 |
| IRON | Disc Medicine, Inc. | $66.62 | 2.51B | — | — | — | — | -11.07 | 3.17 | — | -7.50 | -21.38 | 3.17 | 0.00% | — | — | -35.86% | 717.87% | -32.55% | 0.00 | -65.43 | 21.94 | 21.59 | 0.43 | 5177.00% | — | 9202.00% | -7.72% | -4.92 | 551.51% | 0.00% | 0.00% | 0.00% | -6.61 | -8.60 | — | 20.31 |
| LEGN | Legend Biotech Corporatio… | $19.00 | 1.75B | +139% | +396,718% | -91% | — | -20.39 | 3.10 | 5.14 | -21.66 | — | 3.72 | 62.60% | -48.35% | -28.22% | -13.80% | -112.36% | -8.99% | 0.34 | -14.03 | 4.62 | 4.49 | -0.56 | -6701.00% | 11997.00% | -6199.00% | -4.91% | -0.52 | -58.59% | 0.00% | 0.00% | 0.00% | -8.08 | -15.50 | 3.91 | 2.18 |
| PBH | Prestige Consumer Healthc… | $69.30 | 3.33B | +25% | -46% | -31% | -42% | 19.70 | 2.30 | 3.72 | 14.29 | 684.50 | -4.28 | 55.76% | 29.60% | 18.86% | 12.30% | 9.20% | 6.39% | 0.57 | 7.07 | 4.20 | 2.74 | 2.61 | 288.00% | 110.00% | 164.00% | 5.76% | 2.36 | 8.80% | 0.00% | 0.00% | 4.69% | 15.36 | 21.27 | 4.55 | 3.04 |
| SGRY | Surgery Partners, Inc. | $15.50 | 2B | +214% | -38% | — | — | 242.66 | 1.69 | 0.97 | 12.90 | 18.60 | -0.91 | 23.94% | 11.20% | -5.40% | 0.66% | 2.77% | 0.17% | 2.07 | 1.73 | 1.79 | 1.36 | 6.85 | 130444.00% | 1352.00% | 229.00% | 6.91% | 0.48 | 4.16% | 0.00% | 0.00% | 0.00% | 18.54 | 30.84 | 2.08 | 0.91 |
| SRRK | Scholar Rock Holding Corp… | $44.27 | 4.52B | — | — | — | — | -14.59 | 9.75 | — | -13.57 | -60.50 | 9.81 | 0.00% | — | — | -82.95% | -14081.23% | -62.67% | 0.18 | -36.87 | 9.61 | 9.36 | 0.47 | 2412.00% | — | 3837.00% | -5.59% | -4.28 | -11231.68% | 0.00% | 0.00% | 2.02% | -12.78 | -16.03 | — | 16.84 |
| ZLAB | Zai Lab Limited | $19.22 | 2.13B | +50% | -49% | — | — | -11.49 | 2.82 | 4.38 | -9.81 | — | 3.16 | 58.60% | -49.86% | -38.15% | -22.56% | -97.09% | -14.89% | 0.31 | -44.05 | 2.45 | 1.91 | 2.88 | -3846.00% | 1533.00% | -4251.00% | -7.88% | -0.36 | -68.36% | 0.00% | 0.00% | 7.89% | -6.77 | -9.77 | 3.37 | -0.13 |
About LivaNova PLC
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.
- CEO
- Vladimir A. Makatsaria
- Employees
- 2.9K
- Beta
- 0.94
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($36.57 ÷ $61.00) − 1 = -40.05% (DCF, example).